Statement Of Unitholders' Equity

Oncolys BioPharma Inc. - Filing #7269903

Concept As at
2024-12-31
As at
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
As at
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
As at
2024-12-31
As at
2024-12-31
2024-01-01 to
2024-12-31
As at
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
As at
2024-12-31
2024-01-01 to
2024-12-31
As at
2024-12-31
As at
2024-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
Statement of unitholders' equity
Statement of unitholders' equity
Net assets
7,680,000 JPY
-5,057,978,000 JPY
2,694,489,000 JPY
2,752,209,000 JPY
5,108,160,000 JPY
-142,000 JPY
2,694,489,000 JPY
-5,057,978,000 JPY
2,744,529,000 JPY
14,683,000 JPY
3,623,165,000 JPY
1,474,097,000 JPY
-3,373,199,000 JPY
1,459,413,000 JPY
1,209,590,000 JPY
1,209,590,000 JPY
-142,000 JPY
-3,373,199,000 JPY
-1,434,694,000 JPY
-142,000 JPY
2,159,269,000 JPY
586,425,000 JPY
586,425,000 JPY
2,151,589,000 JPY
3,000,000,000 JPY
-1,434,694,000 JPY
7,680,000 JPY
Changes during period
Net changes in items other than shareholders' equity
-7,003,000 JPY
-7,003,000 JPY
7,003,000 JPY
7,003,000 JPY
Total changes during period
-1,684,778,000 JPY
-7,003,000 JPY
JPY
1,484,995,000 JPY
-1,684,778,000 JPY
1,278,112,000 JPY
1,484,898,000 JPY
1,285,115,000 JPY
1,484,898,000 JPY
-692,175,000 JPY
623,165,000 JPY
-1,938,505,000 JPY
JPY
-685,172,000 JPY
7,003,000 JPY
623,165,000 JPY
-1,938,505,000 JPY
623,165,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.